Cardiovascular outcomes in hypertensive patients: Comparing single-agent therapy with combination therapy

Journal of Hypertension

Volumn 30, Issue 11, 2012, Pages 2213-2222

  Weber, Michael A ^a   Julius, Stevo ^b   Kjeldsen, Sverre E ^c   Jia, Yan ^d   Brunner, Hans R ^e   Zappe, Dion H ^d   Hua, Tsushung A ^d   McInnes, Gordon T ^f   Schork, Anthony ^b   Mancia, Giuseppe ^g   Zanchetti, Alberto ^h  

^a Downstate Health Sciences University   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g SAN GERARDO HOSPITAL   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

blood pressure control; combination therapy; hypertension; major cardiovascular events

Indexed keywords

AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 84867744229     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283582ed6     Document Type: Article

References (18)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National high blood pressure education program coordinating committee: seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003; 42:1206-1252.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): 2007 guidelines for the management of arterial hypertension. J Hypertens 2007; 25:1105-1187.
3. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr, et al., International Society on Hypertension in Blacks. Management of high blood pressure in blacks: an update of the International Society on Hypertension in blacks consensus. Hypertension 2010; 56:780-800.
4. Julius S, Kjeldsen SE, Weber MA, Brunner HR, Ekman S, Hansson L, et al., for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363:2022-2031.
5. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288:2981-2997.
6. Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG, Caulfield M, et al., for the ASCOT investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366:907-913.
7. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585.
8. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304:61-68.
9. Sleight P, Redon J, Verdacchia P, Mancia G, Gao P, Fagard R, et al., on behalf of the ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27:1360-1369.
10. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihy-pertensive treatment on clinical events in the VALUE trial. Lancet 2004; 363:2049-2051.
11. Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial. Outcomes in patients receiving monotherapy. Hypertension 2006; 48:385-391.
12. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. rationale and design. Blood Press 1998; 7:176-183.
13. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
14. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al., for the ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010; 56:77-85.
15. Messerli FH, Makani H, Benjo A, Romero J, Alviar C, Bangalore S. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring. A meta-analysis of randomized trials. J Am Coll Cardiol 2011; 57:590-600.
16. Zanchetti A, Mancia G. Longing for clinical excellence: a critical outlook into the NICE recommendations on hypertension management-is nice always good? J Hypertens 2012; 30:660-668.
17. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006; 24:2163-2168.
18. Zhang Y, Zhang X, Liu L, Wang Y, Tang X, Zanchetti A, for the FEVER Study Group. Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy: is adding drugs always beneficial? J Hypertens 2012; 30:2202-2212.